Reference
1. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR.
Targeting the progression of chronic kidney disease. Nat Rev Nephrol.
2020; 16:269-288.
2. Amaral S, Hwang W, Fivush B, et al. Association of mortality and
hospitalization with achievement of adult hemoglobin targets in
adolescents maintained on hemodialysis. J Am Soc Nephrol. 2006;
17:2878-2885.
3. Matteucci MC, Wühl E, Picca S, et al. Left ventricular geometry in
children with mild to moderate chronic renal insufficiency. J Am Soc
Nephrol. 2006; 17:218-226.
4. Kular D, Macdougall IC. HIF stabilizers in the management of renal
anemia: from bench to bedside to pediatrics. Pediatr Nephrol. 2019;
34:365-378.
5. Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of
hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis
patients. Am J Kidney Dis. 2009; 53:823-834.
6. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of
erythropoiesis-stimulating agents and adverse outcomes in CKD: a
metaregression analysis. Am J Kidney Dis. 2013; 61:44-56.
7. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the
CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney
Int. 2008; 74:791-798.
8. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as
compared with low hematocrit values in patients with cardiac disease who
are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584-590.
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa
in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;
361:2019-2032.
10. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with
epoetin alfa in chronic kidney disease. N Engl J Med. 2006;
355:2085-2098.
11. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients
with anemia undergoing hemodialysis. N Engl J Med. 2013; 368:307-319.
12. Manns BJ, Tonelli M. The new FDA labeling for ESA–implications
for patients and providers. Clin J Am Soc Nephrol. 2012; 7:348-353.
13. Crathorne L, Huxley N, Haasova M, et al. The effectiveness and
cost-effectiveness of erythropoiesis-stimulating agents (epoetin and
darbepoetin) for treating cancer treatment-induced anaemia (including
review of technology appraisal no. 142): a systematic review and
economic model. Health Technol Assess. 2016; 20:1-588, v-vi.
14. Schmid H. Cost-effectiveness of continuous erythropoietin receptor
activator in anemia. Clinicoecon Outcomes Res. 2014; 6:319-330.
15. Rostoker G. When should iron supplementation in dialysis patients be
avoided, minimized or withdrawn? Semin Dial. 2019; 32:22-29.
16. Besarab A, Provenzano R, Hertel J, et al. Randomized
placebo-controlled dose-ranging and pharmacodynamics study of roxadustat
(FG-4592) to treat anemia in nondialysis-dependent chronic kidney
disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015; 30:1665-1673.
17. Chen N, Qian J, Chen J, et al. Phase 2 studies of oral
hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for
treatment of anemia in China. Nephrol Dial Transplant. 2017;
32:1373-1386.
18. Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in
Patients Undergoing Long-Term Dialysis. N Engl J Med. 2019;
381:1011-1022.
19. Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in Patients with
Kidney Disease Not Receiving Dialysis. N Engl J Med. 2019;
381:1001-1010.
20. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3,
Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of
Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. J
Am Soc Nephrol. 2020; 31:1628-1639.
21. Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A Phase 3, Multicenter,
Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of
Roxadustat for the Treatment of Anemia in Japanese
Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients
Not on Dialysis. Nephron. 2020; 144:372-382.
22. Thompson S, James M, Wiebe N, et al. Cause of Death in Patients with
Reduced Kidney Function. J Am Soc Nephrol. 2015; 26:2504-2511.
23. Wen Y, Xu Y, Tian H, et al. Cardiovascular Protective Effects of
Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in
the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a
Randomized Controlled Trial. Front Med (Lausanne). 2022; 9:783387.
24. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with
darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;
368:1210-1219.
25. Chang WT, Lo YC, Gao ZH, Wu SN. Evidence for the Capability of
Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to
Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Int J Mol Sci. 2019; 20.
26. Tang M, Zhu C, Yan T, et al. Safe and Effective Treatment for Anemic
Patients With Chronic Kidney Disease: An Updated Systematic Review and
Meta-Analysis on Roxadustat. Front Pharmacol. 2021; 12:658079.
27. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592)
Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance
Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label,
Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Am J Kidney Dis. 2016; 67:912-924.
28. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase
Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Am J Kidney Dis. 2017; 69:815-826.
29. Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the
treatment of anemia in chronic kidney disease patients not on dialysis:
a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Nephrol Dial Transplant. 2021; 36:1629-1639.
30. Miki K, Nakamura Y, Yokoyama T, Kamiyama M, Ishii Y. Therapeutic
Effect of Roxadustat on Patients With Posttransplant Anemia. Transplant
Proc. 2022; 54:671-677.
31. Hirai K, Kaneko S, Minato S, et al. Effects of roxadustat on anemia,
iron metabolism, and lipid metabolism in patients with non-dialysis
chronic kidney disease. Front Med (Lausanne). 2023; 10:1071342.
32. Nguyen AD, McDonald JG, Bruick RK, DeBose-Boyd RA. Hypoxia
stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase through accumulation of lanosterol and hypoxia-inducible
factor-mediated induction of insigs. J Biol Chem. 2007; 282:27436-27446.
33. Fang T, Ma C, Zhang Z, Sun L, Zheng N. Roxadustat, a HIF-PHD
inhibitor with exploitable potential on diabetes-related complications.
Front Pharmacol. 2023; 14:1088288.
34. Zhang X, Zhang Y, Wang P, et al. Adipocyte Hypoxia-Inducible Factor
2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism.
Cell Metab. 2019; 30:937-951.e935.
35. Deguchi H, Ikeda M, Ide T, et al. Roxadustat Markedly Reduces
Myocardial Ischemia Reperfusion Injury in Mice. Circ J. 2020;
84:1028-1033.
36. Ma X, Dong Z, Liu J, et al. β-Hydroxybutyrate Exacerbates Hypoxic
Injury by Inhibiting HIF-1α-Dependent Glycolysis in
Cardiomyocytes-Adding Fuel to the Fire? Cardiovasc Drugs Ther. 2022;
36:383-397.
37. Provenzano R, Szczech L, Leong R, et al. Efficacy and Cardiovascular
Safety of Roxadustat for Treatment of Anemia in Patients with
Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical
Trials. Clin J Am Soc Nephrol. 2021; 16:1190-1200.
38. Hölscher M, Schäfer K, Krull S, et al. Unfavourable consequences of
chronic cardiac HIF-1α stabilization. Cardiovasc Res. 2012; 94:77-86.
39. Janbandhu V, Tallapragada V, Patrick R, et al. Hif-1a suppresses
ROS-induced proliferation of cardiac fibroblasts following myocardial
infarction. Cell Stem Cell. 2022; 29:281-297.e212.
40. Miao AF, Liang JX, Yao L, Han JL, Zhou LJ. Hypoxia-inducible factor
prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal
ischemia/reperfusion injury by inhibiting inflammation. Ren Fail. 2021;
43:803-810.
41. Yu J, Wang S, Shi W, et al. Roxadustat prevents Ang II hypertension
by targeting angiotensin receptors and eNOS. JCI Insight. 2021; 6.
42. Feng X, Wang S, Sun Z, et al. Ferroptosis Enhanced Diabetic Renal
Tubular Injury via HIF-1α/HO-1 Pathway in db/db Mice. Front Endocrinol
(Lausanne). 2021; 12:626390.
43. Czock D, Keller F. Clinical Pharmacokinetics and Pharmacodynamics of
Roxadustat. Clin Pharmacokinet. 2022; 61:347-362.
Figure Legends